FDA accepts Alvotech and Teva’s BLA for AVT05, advancing first golimumab biosimilar in the U.S.

Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals have confirmed that the U.S. Food and Drug Administration has accepted the Biologics License Application for AVT05, a proposed biosimilar to golimumab—marketed as SIMPONI and SIMPONI ARIA by Johnson & Johnson’s Janssen division. The FDA’s decision to begin its formal review marks a pivotal regulatory milestone for Alvotech’s U.S. pipeline and positions the company to introduce the nation’s first golimumab biosimilar.

The Iceland-based biosimilars specialist stated that the filing was supported by positive topline data from a confirmatory clinical study comparing AVT05 to the reference golimumab in adults with moderate-to-severe rheumatoid arthritis, as well as pharmacokinetic and safety data from an earlier Phase I trial. Together, these datasets are expected to underpin the FDA’s assessment of biosimilarity, immunogenicity, and manufacturing consistency. The review is projected to conclude in the fourth quarter of 2025, pending successful inspection outcomes and data verification.

For Alvotech and Teva, the milestone deepens their biosimilars collaboration in the U.S., expanding on prior submissions for other monoclonal antibodies such as AVT02 (adalimumab) and AVT06 (aflibercept). The companies said they expect AVT05 to broaden patient access to affordable biologic therapies in chronic inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Why FDA acceptance for AVT05 signals Alvotech’s deepening foothold in U.S. biosimilars

The FDA’s acceptance of the AVT05 Biologics License Application indicates that the submission has passed the agency’s completeness check, allowing full scientific review to begin. While acceptance does not imply approval, it validates that Alvotech’s manufacturing and analytical documentation meets regulatory standards for consideration.

This milestone carries strategic weight for Alvotech’s business model, which is built around vertical integration of biologic manufacturing, analytical testing, and regulatory submission capabilities. It also provides a timeline for investors and healthcare stakeholders to anticipate a possible U.S. market debut in 2026, assuming the FDA grants approval on schedule.

AVT05’s target molecule, golimumab, generated more than $1.5 billion in annual U.S. sales according to IQVIA estimates, making it one of the few remaining TNF-alpha inhibitors without an approved biosimilar. Entry of a competitor could significantly expand price competition and payer options within the TNF inhibitor class, joining adalimumab and etanercept biosimilars already in market circulation.

For Teva, which holds exclusive U.S. commercialization rights under its partnership with Alvotech, the approval would extend its biosimilar portfolio into new immunology markets. The company has emphasized its focus on maximizing biosimilar adoption by leveraging its established relationships with U.S. health systems, pharmacy benefit managers, and specialty distributors.

How Alvotech’s regulatory history informs investor sentiment around AVT05’s review trajectory

Investor sentiment toward Alvotech has been cautious yet constructive, reflecting both the opportunity in its expanding U.S. pipeline and the lingering shadow of prior FDA complete response letters for other biologics. Those setbacks were primarily related to manufacturing inspection findings rather than clinical data integrity, which the company has since addressed through process remediations and facility enhancements.

The AVT05 filing demonstrates that Alvotech’s regulatory engagement with the FDA has matured, allowing it to pursue parallel reviews across multiple biosimilar candidates. Analysts have noted that this trajectory may improve the company’s credibility in the U.S. market, provided inspection results confirm sustained compliance.

Market watchers are also framing AVT05 within Alvotech’s broader biosimilar sequencing strategy. With AVT06 (aflibercept) already under FDA review and AVT02 (adalimumab) having achieved approval in select regions, the company appears intent on launching a multi-product wave across autoimmune and ophthalmic indications. Such a coordinated launch plan could help Alvotech capture cross-market efficiencies and improve gross margins over time.

From a valuation standpoint, BLA acceptance often signals a reduction in regulatory risk, which may stabilize investor sentiment and enhance near-term trading momentum. On NASDAQ, Alvotech shares have shown volatility tied to regulatory updates, underscoring the market’s sensitivity to pipeline progress.

What could affect the timing, approval, and commercialization of AVT05 in the U.S.

Despite the positive development, several contingencies could affect AVT05’s ultimate approval and launch. The FDA must conduct comprehensive manufacturing inspections, validate analytical data, and confirm interchangeability testing standards. If deficiencies are identified, the agency may issue a Complete Response Letter (CRL), delaying market entry.

Commercial dynamics also matter. Once approved, biosimilars face hurdles such as formulary inclusion, payer contracting, and provider adoption—factors that can delay meaningful market share capture. However, Teva’s experience with payer engagement and Alvotech’s established global supply infrastructure may mitigate some of these challenges.

Legal or patent settlements with the reference biologic manufacturer could also determine launch timing. The companies have not disclosed any litigation updates related to golimumab, but given industry precedent, settlements could establish defined market entry dates.

For healthcare systems, the arrival of a golimumab biosimilar would mark a turning point for TNF inhibitor accessibility. Golimumab’s unique once-monthly dosing profile makes it a key biologic for patients requiring sustained remission control, and biosimilar entry could reduce treatment costs by 20–40 percent, based on previous market analogs.

How the AVT05 milestone strengthens global biosimilar competition and Alvotech’s growth horizon

The FDA’s acceptance of Alvotech and Teva’s AVT05 BLA reinforces the accelerating globalization of biosimilar competition. Europe already hosts several golimumab biosimilars under review, but the U.S. market has remained exclusive to Janssen’s originator brands. By advancing AVT05 to formal FDA review, Alvotech positions itself as a first-mover contender in one of the last untapped TNF inhibitor segments.

From a corporate-strategy standpoint, the milestone supports Alvotech’s vision of end-to-end biosimilar manufacturing independence—from cell-line development through large-scale fill-finish—which enhances supply reliability and cost control. It also strengthens the firm’s standing with strategic investors seeking exposure to biologic affordability trends.

Should the FDA complete review by late 2025 without issuing a CRL, Alvotech and Teva could initiate pre-launch market education and contracting in early 2026. The event would mark Alvotech’s second major commercial entry in the U.S., broadening its therapeutic reach and solidifying its presence in autoimmune disease management.

The broader ripple effect extends beyond Alvotech itself. Each successful regulatory milestone for biosimilars reshapes payer negotiations and formulary strategy across the U.S. healthcare system. Pharmacy benefit managers increasingly use biosimilar competition as leverage to renegotiate contracts with originator biologics, and the arrival of a golimumab biosimilar would provide a fresh pricing benchmark. This trend is already visible in adalimumab markets, where net prices have declined by up to 60 percent since the entry of biosimilars in 2023. If similar dynamics emerge around golimumab, analysts expect total savings for the U.S. healthcare system to exceed several hundred million dollars annually once multiple competitors enter.

For Alvotech, those economics are critical to sustaining profitability amid global price compression. The company’s vertically integrated Reykjavik manufacturing model gives it a cost advantage, allowing it to maintain competitive margins even as prices fall. Moreover, Teva’s U.S. commercial footprint offers an efficient go-to-market platform—one that could be replicated for future launches across other therapeutic categories such as oncology, ophthalmology, and endocrinology.

The AVT05 milestone is more than a regulatory achievement; it’s a strategic validation of Alvotech’s multi-asset biosimilar playbook. The company is not merely pursuing product approvals but constructing a scalable biosimilar infrastructure capable of addressing global affordability gaps in biologic medicine. As payers, physicians, and patients continue shifting toward high-quality, lower-cost biologic alternatives, Alvotech’s success in securing timely approvals could transform it from a challenger brand into one of the central architects of the next era in immunology therapeutics.